Alzheimers Treatment

Health IT

A look at life science innovation brought on by physician-biopharm tech hybrids

In this series, Dialogues+ is taking a look at innovation brought about through collaborations between physicians and biopharmaceutical/medical technology companies. Today, we look to potential future innovations and recent developments from the National Institutes of Health. Accelerating Medicines Partnership In February 2014, the National Institutes of Health (NIH) announced a new public-private partnership, the Accelerating […]

By Jon Tripp
presented by
presented by
Pharma

Startup Alzheon’s proposal for Alzheimer’s drug success adds new science to old, failed trials

From a commercial perspective, the last few decades of Alzheimer’s drug development have largely been a wash of promising disease-altering drugs failing to demonstrate efficacy in late-stage trials. For startup Alzheon, though, those failures have left behind a trail of valuable clinical and biomarker data that it thinks could lead to hidden treasure. Alzheon launched […]

By Deanna Pogorelc
MedCity Influencers

Obesity: A Risk Factor for Alzheimer’s

This post is part of ongoing coverage of Cleveland Clinic’s 2013 Medical Innovation Summit: Finding Balance through Innovation. Obesity, Diabetes & the Metabolic Crisis. Much of the current research of Alzheimer’s disease is conducted in patients who are already in cognitive decline. Also, too little research is being conducted on the long-term impact that chronic […]

By Cleveland Clinic
Devices & Diagnostics

Navidea’s Alzheimer’s imaging agent moves into Phase 3 with Siemens deal, SBIR grant

Navidea Biopharmaceuticals (NYSE:NAVB) is getting some financial support from the NIH for its Alzheimer’s diagnostic technology as it advances into Phase 3 development. The National Institute of Aging awarded up to $1.8 million for a late-stage clinical trial of the Navidea’s PET beta-amyloid imaging agent, the company said. NAV4694 is designed to help clinicians detect […]

By Deanna Pogorelc